Octreotide vs AOD-9604
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Octreotide
Octreotide (Sandostatin) is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid tumors, and VIPomas. It inhibits growth hormone and various GI hormones.
Full details →AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.
Full details →Side-by-Side Comparison
| Aspect | Octreotide | AOD-9604 |
|---|---|---|
| Mechanism | Binds to somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit GH, glucagon, insulin, and gastric secretions. Reduces blood flow to GI tract and inhibits tumor hormone secretion. | Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors. |
| Typical Dosage | Varies by indication. Acromegaly: 50-100mcg three times daily initially, up to 500mcg TID. LAR (long-acting): 20-30mg IM every 4 weeks. | Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg. |
| Administration | Subcutaneous injection for immediate-release (between meals). Intramuscular for LAR depot form. Requires monitoring of gallbladder, glucose, and thyroid. | Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects. |
| Side Effects | GI effects (diarrhea, nausea, abdominal pain), gallstones (up to 25% of long-term users), injection site reactions, and blood glucose changes. | Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH. |
| Best For |